Embecta Corp(EMBC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 23 at 4:00 AM ET (Korea 9/23 17:00)
Full metrics table
| Index | RUT | P/E | 3.77 | EPS (ttm) | 1.48 | Insider Own | 8.24% | Shs Outstand | 56.7M | Perf Week | 9.82% |
| Market Cap | 0.32B | Forward P/E | 3.17 | EPS next Y | -3.95% | Insider Trans | 2.38% | Shs Float | 52.0M | Perf Month | 6.88% |
| Enterprise Value | 1.60B | PEG | - | EPS next Q | 0.29 | Inst Own | 85.38% | Short Float | 12.05% | Perf Quarter | 78.59% |
| Income | 0.09B | P/S | 0.31 | EPS this Y | -37.8% | Inst Trans | -16.31% | Short Ratio | 3.89 | Perf Half Y | -38.1% |
| Sales | 1.02B | P/B | - | EPS next 5Y | -12.89% | ROA | 7.22% | Short Interest | 6.27M | Perf YTD | -52.95% |
| Book/sh | -10.81 | P/C | 1.45 | EPS past 3/5Y | -25.52% - | ROE | - | 52W High | -62.51% ($14.91) | Perf Year | -61.69% |
| Cash/sh | 3.85 | P/FCF | 1.92 | Sales past 3/5Y | -1.47% -0.1% | ROIC | 11.83% | 52W Low | 101.81% ($2.77) | Perf 3Y | -63.15% |
| Dividend Est. | $0.25 (4.51%) | EV/EBITDA | 4.95 | EPS Y/Y TTM | 4.11% | Gross Margin | 59.63% | Volatility(W/M) | 3.85% 4.94% | Perf 5Y | - |
| Dividend TTM | 0.32 | EV/Sales | 1.57 | Sales Y/Y TTM | -7.6% | Oper. Margin | 26.38% | ATR (14) | 0.27 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/27 | Quick Ratio | 1.17 | EPS Q/Q | -53.64% | Profit Margin | 8.59% | RSI (14) | 62.94 | Recom | 3.25 |
| Dividend Gr. 3/5Y | 58.74% - | Current Ratio | 1.68 | Sales Q/Q | -8.05% | SMA20 | 6.57% ($5.25) | Beta | 0.85 | Target Price | $4 |
| Payout | 37.05% | Debt/Eq | - | Earnings | 2026/8/7 | SMA50 | 22.78% ($4.55) | Rel Volume | 0.42 | Prev Close | $5.3 |
| Employees | 1850 | LT Debt/Eq | - | EPS/Sales Surpr. | 110.68% 6.75% | SMA200 | -22.96% ($7.26) | Avg Volume(3M) | 1.61M | Price | $5.59 |
| IPO | 2022/3/22 | Option/Short | Yes/Yes | Trades | 5570 | Volume | 681,309 | Change | 5.47% |
Company
EMBC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 Embecta (EMBC) is a global medical device company specializing in insulin delivery solutions for diabetes patients. Its core product, pen needles, are disposable sterile needles that attach to insulin pen injectors, generating a stable stream of recurring revenue due to their nature as consumables requiring repeated purchases. The company supplies its products to numerous countries through its global distribution network.
Over the past 1 year, on the lower side
63% below its 1-year high.
EMBC makes money exceptionally well
26.38% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -37.8% this year.
Tap to view numbers
The price looks about right
Trading at 3.8 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is negative
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -63.1% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 4.51% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 85.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ABLS 0.01%
XHE 0.01%
DEEP 0.01%
SIXS 0.01%
SQLV 0.00%It ranks #4 in the industry
Based on market cap of $317M.
EMBC $317M PER 3.8
ISRG $142B PER 46.1
BDX $50B PER 55.2
MDLN $45B PER 40.4
FAQ
What kind of company is EMBC?
EMBC belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of EMBC?
The market cap of EMBC is approximately $317M, ranking 3,661 within its sector.
Does EMBC pay dividends?
EMBC has a dividend yield of approximately 4.51%, with an annual dividend of $0.25.
What is the P/E ratio of EMBC?
EMBC has a P/E ratio of approximately 3.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for EMBC?
EMBC has recorded a 52-week high of $14.91 and a low of $2.77.
